Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 15 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 11274342

    Systems and methods for sequencing T cell receptors and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  2. US 11267893

    Anti-IL36R antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  3. US 11261248

    Restricted immunoglobulin heavy chain mice

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted
  4. US 11253572

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  5. US 11254752

    Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  6. US 11248044

    Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted
  7. US 11241498

    Room temperature stable lyophilized protein

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  8. US 11241499

    Human serum albumin in formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  9. US 11214621

    Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted
  10. US 11208458

    Compositions and methods for internalizing enzymes

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  11. US 11191844

    Multispecific antigen-binding molecules and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  12. US 11186625

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  13. US 11180540

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  14. US 11178860

    Humanized C5 animals

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  15. US 11174305

    Human antibodies to Fel d1 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  16. US 11174283

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  17. US 11168111

    Readily isolated bispecific antibodies with native immunoglobulin format

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  18. US 11167004

    Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted
  19. US 11155633

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  20. US 11155621

    Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  21. US 11155598

    GPR156 variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  22. US 11142578

    Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted
  23. US 11130999

    Cas-ready mouse embryonic stem cells and mice and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted
  24. US 11129903

    Multispecific antigen-binding molecules and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted